Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship.
Levendag PC, Teguh DN, Voet P, van der Est H, Noever I, de Kruijf WJ, Kolkman-Deurloo IK, Prevost JB, Poll J, Schmitz PI, Heijmen BJ. Levendag PC, et al. Among authors: prevost jb. Radiother Oncol. 2007 Oct;85(1):64-73. doi: 10.1016/j.radonc.2007.07.009. Epub 2007 Aug 21. Radiother Oncol. 2007. PMID: 17714815
Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.
van der Voort van Zyp NC, Prévost JB, van der Holt B, Braat C, van Klaveren RJ, Pattynama PM, Levendag PC, Nuyttens JJ. van der Voort van Zyp NC, et al. Among authors: prevost jb. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):31-7. doi: 10.1016/j.ijrobp.2009.04.080. Epub 2009 Oct 26. Int J Radiat Oncol Biol Phys. 2010. PMID: 19864077 Clinical Trial.
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A. Coudert B, et al. Among authors: prevost jb. Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30. Lancet Oncol. 2014. PMID: 25456368 Clinical Trial.
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L. Coudert B, et al. Among authors: prevost jb. EClinicalMedicine. 2020 Nov 4;28:100566. doi: 10.1016/j.eclinm.2020.100566. eCollection 2020 Nov. EClinicalMedicine. 2020. PMID: 33205032 Free PMC article.
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Moore N; FUJI Investigators. Rouyer M, et al. Br J Cancer. 2019 Dec;121(12):1001-1008. doi: 10.1038/s41416-019-0611-6. Epub 2019 Nov 13. Br J Cancer. 2019. PMID: 31719685 Free PMC article.
22 results